BMY

#127
Bristol-Myers Squibb Co.
58.16 USD
+0.12%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
58.14
58.32
Rango anual
42.52
62.89
Cambio diario
+0.12%
Variación mensual
-2.17%
Variación en los últimos 6 meses
+32.88%
Cambio anual
+13.55%
Cierres anteriores
58.09
Abrir
58.26
Bid
Ask
Mínimo
58.14
High
58.32
Volumen
1 284
Ver el calendario completo

Financials

Visión general Informes Estadísticas Dividendos
Trimestre Año
  • Market Capitalization 118.44 B
  • Employee 33 K
  • Founded N/A
  • CEO Chris Boerner
  • Website www.bms.com
  • Headquarter Delaware, United States
  • FIGI BBG000DQLV23
  • Industry Technology
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
15.59
Relación precio/flujo de caja
2.28
Dividendos por acción
2.49
Rendimiento por dividendo, %
4.62

Bristol-Myers Squibb Company

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2024, 71% of the company's revenues came from the United States. The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000.

Noticias